Daiwa Securities Group Has Lowered Expectations for Medtronic (NYSE:MDT) Stock Price

Medtronic (NYSE:MDT) had its target price lowered by analysts at Daiwa Securities Group from $117.00 to $115.00 in a research report issued on Friday,MarketScreener reports. The firm presently has a “buy” rating on the medical technology company’s stock. Daiwa Securities Group’s target price would suggest a potential upside of 17.83% from the stock’s current price.

A number of other research analysts have also commented on the company. Robert W. Baird lowered their price objective on Medtronic from $103.00 to $100.00 and set a “neutral” rating on the stock in a report on Wednesday, February 18th. Jefferies Financial Group reissued a “hold” rating and issued a $110.00 price target on shares of Medtronic in a research report on Wednesday, November 19th. Leerink Partners decreased their price objective on shares of Medtronic from $120.00 to $119.00 and set an “outperform” rating for the company in a report on Wednesday, February 18th. Royal Bank Of Canada raised their target price on shares of Medtronic from $111.00 to $118.00 and gave the company an “outperform” rating in a research note on Wednesday, November 19th. Finally, CICC Research assumed coverage on shares of Medtronic in a research report on Friday, January 30th. They set an “outperform” rating for the company. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $110.74.

Medtronic Trading Up 0.6%

Medtronic stock opened at $97.60 on Friday. The firm has a market cap of $125.31 billion, a price-to-earnings ratio of 27.19, a price-to-earnings-growth ratio of 2.45 and a beta of 0.71. The firm’s 50 day moving average price is $98.93 and its two-hundred day moving average price is $96.89. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.54. Medtronic has a 1 year low of $79.55 and a 1 year high of $106.33.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.34 by $0.02. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The company had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. During the same period in the previous year, the firm posted $1.38 earnings per share. The company’s revenue for the quarter was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, research analysts predict that Medtronic will post 5.46 EPS for the current fiscal year.

Insider Buying and Selling at Medtronic

In other news, EVP Harry Skip Kiil sold 52,524 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the sale, the executive vice president directly owned 32,768 shares in the company, valued at approximately $3,201,761.28. The trade was a 61.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.26% of the company’s stock.

Hedge Funds Weigh In On Medtronic

Hedge funds have recently made changes to their positions in the business. Brighton Jones LLC lifted its holdings in Medtronic by 1,368.0% during the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock worth $3,194,000 after buying an additional 37,265 shares in the last quarter. Sivia Capital Partners LLC raised its position in shares of Medtronic by 9.6% during the second quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock worth $380,000 after acquiring an additional 381 shares during the last quarter. IFG Advisory LLC lifted its stake in shares of Medtronic by 5.4% during the second quarter. IFG Advisory LLC now owns 37,467 shares of the medical technology company’s stock valued at $3,266,000 after acquiring an additional 1,918 shares during the period. Creative Financial Designs Inc. ADV boosted its holdings in Medtronic by 3.8% in the second quarter. Creative Financial Designs Inc. ADV now owns 26,903 shares of the medical technology company’s stock valued at $2,345,000 after acquiring an additional 997 shares during the last quarter. Finally, Great Lakes Retirement Inc. increased its position in Medtronic by 4.8% in the second quarter. Great Lakes Retirement Inc. now owns 16,648 shares of the medical technology company’s stock worth $1,463,000 after purchasing an additional 758 shares during the period. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic News Summary

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Positive clinical readout for Altaviva tibial neuromodulation for urinary incontinence — could support future revenue and adoption in restorative/urogynecologic portfolio. Medtronic reports positive findings for Altaviva tibial neuromod
• Positive Sentiment: Analyst coverage remains constructive: consensus “Moderate Buy” and several buy/overweight ratings and raised price targets underpin the stock’s positive bias; company also maintains a steady dividend (annualized ~$2.84, ~2.9% yield). Medtronic PLC Given Average Recommendation of “Moderate Buy” by Analysts
• Neutral Sentiment: Mixed recent share performance and valuation commentary: short-term momentum is cooling (negative returns over recent weeks/months) though 1‑year TSR remains positive — investors are watching whether earnings/guidance sustain the multiple. Assessing Medtronic (MDT) Valuation After Mixed Recent Share Performance
• Neutral Sentiment: Analysis shows MDT has underperformed the S&P 500 over the past year, which may cap sentiment despite company fundamentals — useful context for relative-performance and ETF/sector flows. How Medtronic Impacted The Healthcare Sector on The S&P 500 Chart
• Negative Sentiment: Large insider sale: EVP Harry Skip Kiil sold 52,524 shares (~$5.13M at ~$97.71) and materially reduced his position — raises some investor caution though insiders may sell for personal/liquidity reasons rather than company outlook. Medtronic EVP Harry Skip Kiil Sells 52,524 Shares

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).